中国临床药学杂志

目的 :观察伊贝沙坦对原发性高血压患者降压的疗效及安全性。方法 :采用自身对照开放试验 ,选取 40例原发性高血压患者 ,服用伊贝沙坦 15 0mg·d-1,如 4wk无效加至 30 0mg·d-1,至 8wk。每 2wk随访BP ,HR ,并记录不良反应。结果 :经 8wk治疗 ,伊贝沙坦降压总有效率达 95 % ,平均SBP由 (146 3± 14 7)mmHg降至 (130 9± 11 0 )mmHg ,DBP由 (94 6± 15 2 )mmHg降至 (79 3± 6 8)mmHg ,P <0 0 5。整个治疗期间无明显不良反应发生。结论 :伊贝沙坦是一个安全、有效的降压药物

AIM: To investigate the efficacy and safety of irbesartan in essential hypertensive patients. METHODS: Forty patients of essential hypertension were treated with oral irbesartan, 150 mg·d -1, for 8-week's and were prescribed with 300 mg·d -1 if their blood pressure weren't decreased effectively after 4 wk. Blood pressure, heart rate and adverse durg reactions were measured every 2 wk. RESULTS: After 8 week's treatment, the effective rate was 95%. The mean systolic blood pressure and diastolic blood pressure were decreased obviously (P<0.05). There had no significant adverse drug reactions during the treatment. CONCLUSION: Irbesartan is an effective and safe drug in the treatment of essential hypertension.